HF 701: Relating to a review of anti-obesity medications by the department of health and human services for purposes of the medical assistance program

What it does

This bill relates to the department of health and human services (HHS) review of anti-obesity medication for purposes of the medical assistance program (Medicaid). The bill requires HHS to review anti-obesity medications for effectiveness, comorbidities, cost savings, and eligibility requirements as described in the bill. HHS shall submit a report to the general assembly by December 1, 2025, containing HHS’s findings and proposed eligibility requirements.

House subcommittee · named February 19, 2025

• Rep. Brett Barker (R) · brett.barker@legis.iowa.gov
• Rep. Chad Ingels (R) · chad.ingels@legis.iowa.gov
• Rep. Beth Wessel-Kroeschell (D) · beth.wessel-kroeschell@legis.iowa.gov

Lobbying · 4 for, 0 against

For: American Diabetes Association; Eli Lilly & Co.; Iowa Biotechnology Association; Personal Interest-Matt Chapman

In plain words

1. February 19, 2025Filed in the House and sent to the Health and Human Services committee · as HSB 209
2. February 19, 2025House subcommittee named: Barker, Ingels and Wessel-Kroeschell · as HSB 209
3. February 25, 2025Subcommittee recommended passing it · as HSB 209
4. February 26, 2025Approved by the House committee · as HSB 209
5. February 26, 2025Committee vote: 19–0 · as HSB 209
6. February 28, 2025Filed in the House
7. February 28, 2025Approved by the House committee, and given a new number: HF 701 · as HSB 209
8. April 3, 2025Sent to the House Health and Human Services committee